A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid Tumors

November 11, 2026 updated by: Ipsen

An Open-label Phase I/II, Dose Escalation, Dose Optimization, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity, and Antitumor Activity of IPN60350 as Monotherapy or in Combination With Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to learn about the safety of a new medicine called IPN60350 and how the body responds to it. Researchers will also look for early signs of antitumor activity in adults with locally advanced or metastatic solid tumors.

All participants in this study will receive IPN60350, either alone or in combination with other anticancer therapies.

The study has two parts.

  • Phase Ia (dose escalation) will test IPN60350 at different dose levels to learn which doses are safe and can be given in future parts of the study.
  • Phase Ib (dose optimization and expansion) will test one or more selected dose levels in a larger number of participants. This will help researchers better understand the safety of IPN60350 and whether it shows early signs of antitumor activity in different tumor types.

Each part will consist of the following periods:

  • A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study center.
  • A treatment period where IPN60350 is administered in repeating treatment cycles.

The study includes health assessments, blood tests, tissue samples (biopsies), and imaging scans to help researchers better understand the safety of IPN60350 and its potential effects on tumors.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

205

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participant must be ≥18 years of age, at the time of signing the informed consent.

  • Histologically or cytologically confirmed locally advanced/metastatic solid tumors.

  • Have at least 1 measurable disease per RECIST version 1.1.

  • Participants with solid tumors who have:

    • Relapsed or refractory disease after receiving at least 1 prior therapy known to provide clinical benefit for their disease based on locally approved standard of care; AND
    • No remaining available approved therapy; or for whom locally approved standard therapies are contraindicated or not deemed appropriate by the treating investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

  • Left ventricular ejection fraction (LVEF) >50%.

  • Adequate bone marrow function.

  • Adequate hepatic function and absence of laboratory abnormalities indicating hepatic injury before first dose of study intervention.

  • Adequate renal function before first dose of study intervention.

  • Prothrombin time (PT) or international normalized ratio (INR) ≤1.5× upper limit of normal (ULN).

  • At the time of screening, a tumor tissue specimen is required for enrollment into phase Ia and phase Ib parts of the study.

Exclusion Criteria:

  • Known second malignancy either progressing or requiring active treatment.
  • Has not recovered (i.e., to CTCAE version 6.0 Grade 1 or to baseline) from previous anticancer therapy-induced AEs. Note: Grade ≤2 AEs with no impact on participant safety are exceptions to this criterion and may qualify for the study, e.g., Grade ≤2 hair loss or stable peripheral neuropathy.
  • Major surgery before receiving the first dose of study treatment. Participants must have adequate wound healing and have recovered from surgery related complications/toxicities prior to first dose.
  • Active brain metastases or leptomeningeal metastases.
  • Significant concurrent, uncontrolled medical condition that would put participants at unacceptable risk from study participation or preclude them from complying with study procedures as per investigator assessment, including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.
  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging screening.
  • Clinically significant pulmonary disease that may increase the risk of drug-related pneumonitis, including but not limited to pulmonary fibrosis, severe or uncontrolled chronic obstructive pulmonary disease (COPD), uncontrolled asthma, or ongoing pulmonary infection.
  • Participants with uncontrolled human immunodeficiency virus (HIV). HIV-infected participants are eligible if they meet criteria specified in protocol.
  • Known active infection with hepatitis B virus (HBV) OR hepatitis C virus (HCV). Participants are eligible if they meet criteria described in the protocol.
  • History of allogeneic organ transplantation or graft-versus-host disease.
  • Known hypersensitivity to study drug, other monoclonal antibodies, or any of the excipients including sensitivity to heparin or heparin-induced thrombocytopenia.
  • Clinically significant cardiovascular or cerebrovascular disease including but not limited to acute myocardial infarction, unstable or severe angina pectoris, endoscopic or open-heart cardiac surgery, stroke, transient ischemic attack, cerebral hemorrhage, or cerebral infarction, congestive heart failure, arrhythmia, or uncontrolled hypertension.

Note: Additional protocol specified inclusion/exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Phase Ia: Dose Escalation

Participants will receive IPN60350, at the assigned dose level.

IPN60350 will be administered at the assigned dose level.

Experimental: Phase Ib: Dose Optimization and Expansion

At dose optimization, participants will be randomized to receive IPN60350, at one of the two doses of interest.

IPN60350 will be administered at the assigned dose level.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase Ia: Percentage of Participants With Dose Limiting Toxicities (DLTs)
Time Frame: Up to Day 21 following study drug administration
Up to Day 21 following study drug administration
Phase Ia and Ib: Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Time Frame: From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)

An adverse event (AE) is any unfavorable medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A TEAE is defined as an AE with onset from the first dose of study intervention, until the safety follow-up visit, or prior to the start of a new anticancer treatment, whichever is earlier. TEAEs and TESAEs will be graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0.

From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)
Phase Ib: Objective Response Rate (ORR)
Time Frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as determined by investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
Phase Ib: Percentage of Participants With Dose Interruptions and Permanent Treatment Discontinuations
Time Frame: From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)
From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase Ia: Time to Maximum Observed Drug Concentration (Tmax) of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia: Maximum Observed Drug Concentration (Cmax) of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia: Area Under the Plasma Concentration Time Curve Over a Dosing Interval (AUCtau) of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia: Tmax of Total Antibody (Tab) of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia: Cmax of Tab of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia: AUCtau of Tab of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia: Tmax of Free Toxin of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia: Cmax of Free Toxin of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia: AUCtau of Free Toxin of IPN60350
Time Frame: Within 21 days following drug administration
Within 21 days following drug administration
Phase Ia and Ib: Percentage of Participants With Treatment-Emergent Anti-drug Antibodies (ADA), Including Binding and Neutralizing Antibodies.
Time Frame: From pre-dose on Day 1 up to end of study (up to approximately 3.5 years)
From pre-dose on Day 1 up to end of study (up to approximately 3.5 years)
Phase Ia: Objective Response Rate (ORR)
Time Frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

ORR is defined as the percentage of participants with BOR of CR or PR, as determined by investigator per RECIST version 1.1.

From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
Phase Ib: Duration of Response (DoR)
Time Frame: From first confirmed documented response (CR or PR) to the earliest date of documented disease progression, new anticancer therapy or death due to any cause (up to approximately 3.5 years)

DoR is defined as the time from the first documented evidence of CR or PR until progressive disease, as determined by investigator per RECIST version 1.1, or death from any cause, whichever occurs first.

From first confirmed documented response (CR or PR) to the earliest date of documented disease progression, new anticancer therapy or death due to any cause (up to approximately 3.5 years)
Phase Ib: Progression-free Survival (PFS)
Time Frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

PFS is defined as the time from the date of first IPN60350 administration to the date of the first documented disease progression, as determined by investigator per RECIST version 1.1, or death due to any cause, whichever occurs first.

From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
Phase Ib: Disease Control Rate (DCR)
Time Frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

DCR is defined as the percentage of participants with BOR of CR, PR or stable disease (SD), as determined by investigator per RECIST version 1.1

From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

June 28, 2030

Study Completion (Estimated)

September 30, 2030

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CLIN-60350-450
  • 2026-527553-18-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD Sharing Time Frame

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD Sharing Access Criteria

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe